Preferred Label : Allogeneic Anti-BCMA CAR-transduced T-cells ALLO-715;
NCIt synonyms : ALLO-715 Cells; BCMA Allogeneic CAR T Cells ALLO-715; ALLOCar T ALLO-715;
NCIt related terms : NENDOCABTAGENE ONOGEDLEUCEL;
NCIt definition : A preparation of allogeneic, 'off-the-shelf' (OTS), universal transcription activator-like
effector nuclease (TALEN)-engineered, gene-edited T-lymphocytes that have been transduced
with a vector expressing a chimeric antigen receptor (CAR) containing a single chain
variable fragment (scFv) derived from a monoclonal antibody specific for the human
tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor
receptor superfamily member 17; TNFRSF17), with potential immunostimulating and antineoplastic
activities. Using TALEN technology, the T-cell receptor (TCR) alpha chain (TRAC) and
CD52 genes are deleted from the CAR T-cells. Upon administration, nendocabtagene onogedleucel
specifically recognize and induce selective toxicity in BCMA-expressing tumor cells.
BCMA, a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating
factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF).
BCMA is found on the surfaces of plasma cells, is overexpressed on malignant plasma
cells and plays a key role in plasma cell proliferation and survival. Deletion of
the CD52 gene makes the modified donor T-cells resistant to an anti-CD52 monoclonal
antibody treatment, that is used during lymphodepletion. The knockout of TRAC eliminates
TCR expression and is intended to abrogate the potential induction of graft-versus-host
disease (GvHD) by the donor T-cells. The donor-derived, gene-edited CAR T cells have
reduced production times and have increased availability when compared to autologous
CAR-T cells, which use the patient's own cells and are produced on an individual basis.
In addition, if nendocabtagene onogedleucel cause unacceptable side effects, the incorporated
CD20-based off-switch permits selective depletion of the ALLO-715 cells when the anti-CD20
monoclonal antibody rituximab is administered.;
UNII : Q137JC2CLV;
CAS number : 2783320-97-6;
Molecule name : ALLO 715; ALLO-715;
NCI Metathesaurus CUI : CL979064;
Origin ID : C165779;
UMLS CUI : C5237454;
Semantic type(s)
- Cell [UMLS semantic type]
- concept_is_in_subset
- has_target
